Anu Osinusi

Biography
Anu Osinusi is an infectious diseases physician and biopharmaceutical executive with extensive experience in antiviral drug development. At Gilead Sciences, she leads end-to-end development across a broad portfolio spanning viral hepatitis, respiratory viruses, pandemic preparedness, and emerging viral threats. She has led the development of transformative therapies, including curative treatments for hepatitis C, the first approved antiviral for COVID-19, and the first approved therapy for hepatitis delta. Prior to joining Gilead, Anu served as Clinical Director of the Hepatitis Branch for the DC Partnership for HIV/AIDS Progress, an NIH–DC Department of Health collaboration. She remains adjunct faculty at the University of Maryland and has authored numerous peer-reviewed publications.